

HYBRIGENICS

Press release

Presentation at the American BIO Investor Forum

October 6, 2010 in San Francisco

Paris, October 1, 2010 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and with a 100 % subsidiary dedicated to specialized services in protein interactions, will take part in the 9th Annual BIO Investor Forum organised by the Biotechnology Industry Organisation in San Francisco on October 5 and 6, 2010.

At the event, Hybrigenics' management will present the major strategic breakthroughs achieved during the current financial year, and notably the definitive results of the Phase IIa clinical trials obtained with its flagship product, Inecalcitol, on October 6 at 8.30 am local time, i.e. 5.30 pm Paris time.

Hybrigenics' participation in this prominent North American Forum for the biotechnology sector is in line with the Company's commitment to strengthen its relations with its investors and to increase its visibility within the financial community.

About Hybrigenics

Hybrigenics SA (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere[®], which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Hybrigenics Services SAS is a 100% subsidiary of Hybrigenics, the market leader in Yeast-Two Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

HYBRIGENICS is listed on the Alternext by NYSE Euronext

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics
Rémi Delansorne
CEO
Tel. : +33 (0)1 58 10 38 00
investors@hybrigenics.com

NewCap.
Financial communication
Axelle Vuillermet / Pierre Laurent
Tel. : +33 (0)1 44 71 94 94
hybrigenics@newcap.fr